m+Medelevator.RU
← Поиск публикаций
Materials (Basel, Switzerland) · 2026

Biomedical Materials and Fabrication Methods for Construction of In Vitro Neurovascular Unit Models.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Xu Yuanyuan, Yu Wenlong, Li Yang, Zhang Lei

Аннотация

In vitro neurovascular unit (NVU) models are essential for reproducing blood-brain barrier (BBB) transport and neurovascular cell interactions. However, the literature remains fragmented: biomaterial chemistry, fabrication parameters and organ-on-a-chip architecture are commonly evaluated in isolation, while inconsistent reporting of matrix properties, processing history, cell source, flow and barrier readouts prevents head-to-head comparison and the extraction of transferable design rules. To address this gap, this review integrates biomaterials, manufacturing technologies and organ-on-a-chip engineering within a unified material-process-structure-function framework. We translate endothelial junctions, basement-membrane components and perivascular cells into experimentally actionable material requirements; compare natural, synthetic, semisynthetic and decellularized extracellular-matrix hydrogels; and examine crosslinking, peptide functionalization, stimuli responsiveness, composite-network formation and preparation methods. Findings from Transwell, microfluidic, tubular, self-assembled and 3D-bioprinted BBB systems are used to relate matrix stiffness, degradability, ligand density, permeability, device-body material and fabrication route to barrier maturation, analytical access and reproducibility. By defining matched controls and minimum reporting requirements for chemistry, mechanics, transport and processing, this review provides a practical basis for next-generation BBB models that can improve permeability and efficacy screening in drug discovery, reproduce disease- and patient-specific barrier dysfunction, and support individualized response testing with iPSC- or patient-derived cells.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты